Merrimack Pharmaceuticals, Inc.

MACK

US5903282094

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
15.13 ^USD	-0.13%		-.--%	+12.83%

May. 21	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index	CI
May. 21	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index	CI

Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from NASDAQ Composite Index

May 16, 2024

Merrimack Pharmaceuticals, Inc will be removed from NASDAQ Composite Index

Latest news about Merrimack Pharmaceuticals, Inc.

Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index	May. 20	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index	May. 20	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from NASDAQ Composite Index	May. 16	CI
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024	May. 09	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing	Nov. 16	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index	23-09-17	CI
Insider Buy: Merrimack Pharmaceuticals	23-08-09	MT
Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Completeness Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Dynamic Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2500 Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell Small Cap Comp Growth Index	23-06-23	CI
Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 2000 Growth Index	23-06-23	CI

Chart Merrimack Pharmaceuticals, Inc.

Duration

Period

More charts

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. It is entitled to receive payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. These payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of Onivyde for certain additional clinical indications. ONIVYDE is approved by FDA to market as a first-line treatment of metastatic adenocarcinoma on the pancreas. It is also entitled to receive payments related to its sale of anti-HER3 programs to Elevation Oncology, Inc. The Companyâs wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MERRIMACK PHARMACEUTICALS, INC.	+12.83%	224M
MODERNA, INC.	+46.01%	54.63B
IQVIA HOLDINGS INC.	-6.98%	39.92B
LONZA GROUP AG	+37.07%	38.82B
ICON PUBLIC LIMITED COMPANY	+13.20%	26.86B
CELLTRION, INC.	-11.17%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.25%	12.21B
BIO-TECHNE CORPORATION	+0.31%	12.16B
MEDPACE HOLDINGS, INC.	+25.25%	11.94B